|
|||
Altimmune Inc (ALT)2.48 +0.05 (+2.06%) 06/03/19 [NASDAQ]
2.41 x 3 2.49 x 22
POST-MARKET 2.41 -0.07 (-2.82%) 19:49 ET
for Mon, Jun 3rd, 2019
|
|||
Chart Link⇓ |
|||
https://www.barchart.com/stocks/quotes/ALT |
|||
https://finance.yahoo.com/quote/ALT |
|||
https://www.gurufocus.com/stock/ALT |
|||
|
|||
|
|||
DescriptionAltimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland. |
|||
Notes AA | |||
Notes AR | |||
Altimmune Inc (ALT)
(ALT)
2.48 +0.05 (+2.06%) 06/03/19 [NASDAQ]
2.41 x 3 2.49 x 22
POST-MARKET 2.41 -0.07 (-2.82%) 19:49 ET
QUOTE OVERVIEW for Mon, Jun 3rd, 2019
Category: Pharma & Health
Reviews
There are no reviews yet.
Related products
Pharma & Health
Current Stocks
Pharma & Health
Pharma & Health
Pharma & Health
Pharma & Health
Pharma & Health
Pharma & Health
Be the first to review “Altimmune Inc (ALT)”